These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20224944)

  • 1. Superior efficacy of new medicines?
    van Luijn JC; Gribnau FW; Leufkens HG
    Eur J Clin Pharmacol; 2010 May; 66(5):445-8. PubMed ID: 20224944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of comparator in active control trials of new drugs.
    van Luijn JC; van Loenen AC; Gribnau FW; Leufkens HG
    Ann Pharmacother; 2008 Nov; 42(11):1605-12. PubMed ID: 18957629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome.
    Pignatti F; Aronsson B; Gate N; Vamvakas S; Wade G; Moulon I; Le Courtois P
    Eur J Clin Pharmacol; 2002 Dec; 58(9):573-80. PubMed ID: 12525957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
    Merli G; Spyropoulos AC; Caprini JA
    Ann Surg; 2009 Aug; 250(2):219-28. PubMed ID: 19638915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000--why aren't we doing better?
    Garazzino S; Lutsar I; Bertaina C; Tovo PA; Sharland M
    Int J Antimicrob Agents; 2013 Aug; 42(2):99-118. PubMed ID: 23810180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HTA-Perspective: Challenges in the early assessment of new oncological drugs].
    Wild C; Nachtnebel A
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):129-35. PubMed ID: 23663907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pathway for qualification of novel methodologies in the European Medicines Agency.
    Manolis E; Vamvakas S; Isaac M
    Proteomics Clin Appl; 2011 Jun; 5(5-6):248-55. PubMed ID: 21538915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicines discovery in the 21st century: the case for a stakeholder corporation.
    Dixon J; England P; Lawton G; Machin P; Palmer A
    Drug Discov Today; 2010 Sep; 15(17-18):700-3. PubMed ID: 20678583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State of the art in benefit-risk analysis: medicines.
    Luteijn JM; White BC; Gunnlaugsdóttir H; Holm F; Kalogeras N; Leino O; Magnússon SH; Odekerken G; Pohjola MV; Tijhuis MJ; Tuomisto JT; Ueland Ø; McCarron PA; Verhagen H
    Food Chem Toxicol; 2012 Jan; 50(1):26-32. PubMed ID: 21683115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications.
    Van Cutsem E; Ducreux M
    Nat Rev Clin Oncol; 2016 Feb; 13(2):69-70. PubMed ID: 26667973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.